News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
The initiative aims to connect startups and tech companies with its business units,
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Phase 3 data expected in the second half of 2024
Subscribe To Our Newsletter & Stay Updated
